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Abstract
Background: Radiotherapy (RT) is currently under investigation as part of a trimodality treatment of malignant
pleural mesothelioma (MPM). The introduction of highly conformal radiotherapy (HCRT) technique improved dose
delivery and target coverage in comparison to 3-dimensional conformal radiotherapy (3DCRT). The following study
was undertaken to investigate the clinical outcome of both radiation techniques.
Methods: Thirty-nine MPM patients were treated with neoadjuvant chemotherapy, extrapleural pneumonectomy
(EPP) and adjuvant RT. Twenty-five patients were treated with 3DCRT, and 14 with HCRT (Intensity modulated
radiotherapy or volumetric modulated arc therapy). Overall survival, disease free survival, locoregional recurrence
and pattern of recurrence were assessed. A matched pair analysis was performed including 11 patients of each
group.
Results: After matching for gender, age, histology, tumor stage and resection status, HCRT seemed superior to
3DCRT with a local relapse rate of 27.3% compared to 72.7% after 3DCRT (p = 0.06). The median time to local
relapse was increased by 49% with HCRT in comparison to 3DCRT from 10.9 ± 5.4 months to 16.2 ± 3.1 months
(p = 0.06). The median overall survival was 22.3 ± 15.3 months for HCRT and 21.2 ± 9.2 months for 3DCRT
(p = 0.57). Recurrence analysis showed that in-field local relapses occurred in previously underdosed regions of the
tumor bed in 16% of patients treated with 3DCRT and in 0% of HCRT patients.
Conclusions: The use of HCRT increases the probability of local control as compared to 3DCRT by improving target
volume coverage. HCRT did not improve overall survival in this patient series due to the high rate of distant
recurrences.
Keywords: Mesothelioma, Radiation therapy, Extrapleural pneumonectomy, Volumetric modulated arc therapy,
Intensity modulated radiotherapy, Multimodal therapy
Introduction
Malignant pleural mesothelioma (MPM) is a rare and ag-
gressive malignancy associated with poor prognosis. Al-
though MPM is often initially confined to the hemithorax,
it has a high potential for metastatic spread in the course
of disease [1]. The mainstay of treatment is surgery con-
sisting of either pleurectomy/decortication (PD) or radical
extrapleural pneumonectomy (EPP) in combination with
cisplatin/pemetrexed and, in selected cases, postoperative
radiotherapy [2-5]. The rationale to apply postoperative
radiotherapy after EPP has been the high rate of local
recurrence after EPP alone of about 40% [6].
The pattern of pleural dissemination, infiltrative growth
and the manipulations within the chest cavity during sur-
gery place the entire ipsilateral chest wall at high risk
for post-surgical relapse, especially at the diaphragm
insertion, the pericardium, mediastinum and bronchial
stump. Technically, hemithoracic radiotherapy is challen-
ging due to various reasons. Firstly, the size of the volume
to be treated is large, and may cover up to six liters. Sec-
ondly, the target lies in close proximity to various organs
at risk (OAR) such as the heart, ipsilateral kidney, liver,
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remaining lung, esophagus and/or spinal cord. Thirdly,
the thoracic cavity has a complex shape with its costo-
diaphragmatic recess extending around the liver and the
kidney. Previous publications showed that highly con-
formal radiotherapy (HCRT) such as intensity modulated
radiotherapy (IMRT) or volumetric modulated arc therapy
(VMAT) can improve the dose distribution in respect to
target coverage and dose to OAR [7,8]. However to our
knowledge there is no clinical study published that investi-
gated and compared clinical outcome after both radiation
techniques. In order to verify if the technical improve-
ments introduced with IMRT or VMAT have translated
into a clinical benefit, we evaluated the clinical outcome
of MPM patients treated with chemotherapy, surgery and
3DCRT or HCRT at our institution.
Material and methods
We reviewed the clinical outcome of 39 consecutive
patients treated either with 3DCRT (25 patients) or
HCRT (11 IMRT patients and 3 VMAT patients). Patient
staging was established using FDG-PET/CT and/or
conventional thoraco-abdominal CT. The patients with
clinical stage T1-T3, N0-2, M0, R0-2 were treated with
3 cycles of preoperative chemotherapy (pemetrexed
and cisplatin) followed by EPP and RT [7]. All histo-
logical subtypes were accepted for RT. Patients were
not selected for this review if they had metastatic dis-
ease or a local relapse before the start of RT. The study
was approved by the local ethics committee of the
University Hospital of Zurich.
Radiation techniques
The 3DCRT group was treated between 1999 and 2005.
These patients were treated with 25 × 1.8 Gy = 45 Gy to
the hemithorax and subsequently, in a second series, a
boost of 7 × 1.8 Gy = 12.6 Gy was given to the incom-
pletely resected area (total dose 57.6 Gy). Dose calculation
was performed on Pinnacle planning system (Philips Medical
Systems) for a linear accelerator (Clinac 2100C, Varian
Medical Systems). Details of the treatment technique have
previously been published [7].
HCRT has been used at our institution since 2005 for
the treatment of MPM patients. Of the 14 patients treated
with HCRT, 11 were treated with conventional static field
IMRT and 3 patients with rotational IMRT (volumetric
arc radiotherapy, i.e. Rapid Arc® in the present series).
IMRT and VMAT plans achieved similar dose distri-
butions [9,10]. In the case of HCRT only one series was
applied with 26 × 1.75 Gy = 45.5 Gy delivered to the
hemithorax with a simultaneous integrated boost of 26 ×
2.15 Gy = 55.9 Gy delivered to the R1/R2 region. Planning
and dose calculation was performed on the Eclipse plan-
ning system (Varian Medical Systems, Palo Alto, CA) for a
linear accelerator (Clinac 6EX or Trilogy, Varian Medical
Systems). The treatment technique and dose-volume con-
straints have been previously published [7,10,11].
Follow-Up and recurrence analysis
Patients were followed up every three to four months
with clinical examinations and CT or PET/CT scans.
Local tumor progression or recurrence was defined as
an increasing radiographic abnormality within or par-
tially within the irradiation field. Recurrence adjacent to
the field border but not in-field was defined as marginal
miss recurrence. Regional recurrence was defined as
recurrence in close proximity but not within the irradi-
ated field. Tumor recurrence in the contralateral hemi-
thorax or abdominal cavity was classified as a distant
recurrence [12]. All in-field recurrences were carefully
analyzed by 2 of the authors (JK, PD), in order to assess
if they occurred in previously underdosed areas by com-
paring the respective diagnostic image with the radiation
therapy treatment plan.
Statistics
All survival endpoints as well as tumor recurrence were
measured from the date of treatment start (neoadjuvant
chemotherapy) and were evaluated using the Kaplan
Meier Method. In a subset of the cohort, a matched pair
analysis was performed in order to compare outcome
after 3DCRT and HCRT. For this analysis, the patients
were matched for age, preoperative TNM, R and histology,
and sex (except one pair).
Results
Between 1999 and 2011, 39 patients were treated with
neoadjuvant chemotherapy and EPP followed by RT. All
follow up patients were deceased at the time of this
study.
Matched pair analysis
In the matched pair analysis, 11 HCRT and 11 3DCRT
patients were matched based on tumor staging, resection
status, tumor histology, age and gender (except one pair
were the gender was not matched). In each group 3 pa-
tients had a tumor stage T1N0M0 with resection R0
and 8 patients, tumor stage T2N0M0 with resection R1.
Tumor histology was epithelioid for 6 patients and bi-
phasic for 5 patients in each group. The mean age was
59.6 years and 59.8 years for patient’s in the HCRT and
3DCRT group.
The median time to local relapse was increased by
49% with HCRT in comparison to 3DCRT from 10.9 ±
5.4 months to 16.2 ± 3.1 months (p = 0.06) as displayed
in Figure 1. Three (27.3%) and eight patients (72.7%)
had a local relapse after HCRT and 3DCRT respectively.
Nine HCRT (81.8%) and nine 3DCRT (81.8%) patients
developed metastases within a median time of 18.4 ±
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10.7 months and 10.9 ± 8.6 months (p = 0.21). The differ-
ence in disease free survival between HCRT and 3DCRT
was not significant (p = 0.72). The median overall survivals
were 22.3 ± 15.3 months for HCRT and 21.2 ± 9.2 months
for 3DCRT and are displayed in Figure 2 (p = 0.57).
Outcome of the entire cohort
Fourteen HCRT and 25 3DCRT patients were treated and
reviewed. Patient’s sex, age, tumor characteristics and
resection are displayed on Table 1.
The median overall survival was 20.8 ± 14.4 months for
the HCRT group, and 26.9 ± 11.8 months for the 3DCRT
group (p = 0.48). In the HCRT group, 10 patients (71%)
died of progressive disease and 4 patients (29%) due to
intercurrent disease: one patient died of septic shock, one
of acute myocardial infarction, one of progressive biventri-
cular heart failure and another patient, who was well and
without evidence of disease at two days before his sudden
death most likely also died due to a cardiac event. In
the 3DCRT group 24 patients (96%) died of progressive
disease and one of septic shock (4%).
The local control rates were improved after HCRT
(p = 0.30). Four HCRT patients (28.6%) suffered from
locoregional relapse in comparison to 15 patients (60%)
treated with 3DCRT.
Analysis of tumor recurrence
For patients treated with HCRT, local relapse occurred
in-field in 3 patients (21.4%), all within areas that had
Figure 1 Local control for 11 matched modulated radiotherapy
(HCRT) patients and 11 3-dimensional conformal radiotherapy
(3DCRT) patients.
Figure 2 Overall survival for 11 matched modulated radiotherapy
(HCRT) patients and 11 3-dimensional conformal radiotherapy
(3DCRT) patients.
Table 1 Patient demographics and tumor characteristics
of 39 patients who underwent neoadjuvant
chemotherapy, extrapleural pneumonectomy and
radiotherapy
Characteristic HCRT 3D-CRT
n = 14 n = 25
Sex
• Male 13 22
• Female 1 3
Mean age (years) 61 61
Side
• Right 9 15
• Left 5 10
Tumor histology
• Epithelioid 8 17
• Biphasic 6 8
Initial Tumor stage
• T1 3 15
• T2 10 10
• T3 1 0
Initial Nodal stage
• N0 14 22
• N1 0 1
• N2 0 2
Resection
• R0 4 8
• R1 9 15
• R2 1 2
Abbreviation: HCRT: Highly conformal modulated radiotherapy,
3DCRT: 3-dimensional conformal radiotherapy.
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been treated with doses between 43 Gy to 59 Gy (accord-
ing to our treatment planning protocol 95% of the pre-
scribed 45 Gy (=43 Gy) should enclose the target volume,
which in this case is the tumor bed of the hemithorax,
Table 2) and none in a clearly underdosed region. One pa-
tient (7.1%) had a marginal miss recurrence at the field
border (13 Gy). In the 3DCRT group, twelve patients
(48%) had in-field recurrences in regions treated with
doses between 30 Gy and 56 Gy (Table 3). Notably, in 16%
of patients treated with 3DCRT (4/25) in-field recurrences
occurred in regions that were covered with doses of only
30 to 43 Gy, instead of the prescribed ≥45 Gy. One patient
(4.0%) had a marginal miss recurrence (18 Gy). In one pa-
tient with a regional recurrence (4.0%) the delivered dose
was not possible to define because no diagnostic CT was
available. In one patient (4.0%) the site of recurrence could
not be determined because of missing radiographs during
follow-up.
Distant recurrences occurred in ten patients (71.4%)
treated with HCRT and in twenty 3DCRT patients
(80%). The median time to distant metastases was 18.4 ±
10.7 months in HCRT group and 16.7 ± 7.7 months in
3DCRT group (p = 0.7). In the HCRT group, distant me-
tastases involved only the contralateral chest in three
patients (30%) and only the abdominal cavity in three
patients (30%). Both sites were affected by distant me-
tastases in four further patients (40%).
Discussion
We demonstrate in a retrospective analysis of patients
with MPM and treated at our institution with trimodality
therapy that the use of postoperative highly conformal ra-
diation techniques (HCRT) reduces local recurrence in
comparison to 3DCRT. A recurrence analysis showed that
in the case of 3DCRT 4 of 25 patients (16%) had a local
recurrence in regions that were clearly underdosed ac-
cording to current radiation protocols (doses ≥ 45 Gy are
recommended, e.g. SAKK 17/04) in contrast to 0% of
patients treated with HCRT. This supports the hypothesis
that HCRT should improve local control in comparison to
3DCRT by improving target volume coverage. In our
study patients treated with HCRT showed a tendency for
improved progression free survival and local relapse free
survival but did not benefit in terms of overall survival
due to the high rates of distant relapses.
Local control is important in patients with MPM for
symptom control, but also because some patients might
benefit in terms of improved overall survival. Better local
control after HCRT did not translate into improved
overall survival in our patient series. Remarkably, the
rate of death due to intercurrent disease, most often car-
diac events, was higher after HCRT (29%) in comparison
to 3DCRT (4%). Since cardiac sparing is rather improved
with HCRT the most likely explanation for this differ-
ence is patient selection. The urgent research question,
if postoperative radiotherapy impacts on overall survival
after EPP, is addressed by a randomized study currently
conducted in Switzerland, SAKK 1704. Patient accrual
for this study was terminated in 2012 and the results are
awaited.
Even after trimodality treatment local recurrence re-
mains high in some patient series. In a retrospective
series of 49 patients treated with 3D-conformal RT after
EPP and chemotherapy 67% of all recurrences included
the ipsilateral hemithorax and 25% of all recurrences
were local only [12]. Therefore improvement of radio-
therapy is mandatory. In recent years radiotherapy has
made enormous technical advances. More sophisticated
highly conformal radiation techniques (HCRT) such as
IMRT or rotational RT (VMAT) have become available
and substituted for the older 3DCRT technique. The use
of HCRT enables improvement in the dose distribution
and target volume coverage. This is because with HCRT
even complex target volumes such as the tumor bed of
the costodiaphragmatic recess or the pericardium can be
treated without or with little dose compromise and at
the same time with optimal sparing of the normal tissue
due to a steeper dose fall-off. Thus, the use of HCRT
should intuitively improve treatment outcome in terms
of local tumor control. Our data suggest indeed, that the
use of HCRT bears considerable potential to improve on
hemi-thoracic tumor control rates most likely due to
improved target volume coverage.
The poor local control rates and high rates of in-field
recurrences following 3DCRT in our cohort may be due
to suboptimal dose coverage or the restriction of the target
volume to avoid critical organs, both limitations inherent
to the technique. After 3DCRT 4/24 (16.6%) in-field recur-
rences occurred in regions covered with only 30–43 Gy.
In the case of 3DCRT mixed beams of photons and elec-
trons were used to optimize dose coverage. The match of
these beams often causes cold and hot spots of dose
coverage. Poor matching during daily treatment can result
in >20% dose inhomogeneity in the junction area [7]. In
Table 2 Locoregional recurrences in patients who
underwent highly conformal modulated radiotherapy
Localization Age/sex Histology Time to
recurrence
Dose in
recurrence
region
(Months) (Gray)
In-field recurrence 67/m Epithelioid 10 54
In-field recurrence 62/m Biphasic 15 56–59
In-field recurrence 64/m Epithelioid 10 43–50
Marginal miss 65/m Biphasic 17 13
Recurrence
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addition, as the spinal cord is blocked when the tolerance
dose of 45 Gy is reached, insufficient dose delivery to parts
of the mediastinum has been observed, resulting in under-
dosage to the tumor bed [7].
Favorable tumor control after IMRT as part of a tri-
modality therapy has previously been reported by Rice
et al. [13]. The median overall survival of their 61 patients
treated was 14.2 months with a locoregional recurrence
rate of 13% and only 5% local in-field recurrences re-
ported. The median dose prescribed was only 45 Gy,
and half of all patients received doses even less than
45 Gy. The reason for the comparatively higher local
control rate reported by Rice et al. in comparison to our
study remains unclear. It may be explained by patient
selection and the comparatively short median overall
survival of 14.2 months in comparison to 20.8 months
in the present series and by the retrospective study
design. The shorter median overall survival reported by
Rice et al. could be caused by more advanced tumor
stages (40 T3, 8 T4, 26 N2), more aggressive subtypes
(14 biphasic, 4 sarcomatoid) and the fact that neoadjuvant
chemotherapy was not routinely administered.
With regard to toxicity the major dose limiting organ
for postoperative radiotherapy of MPM is the contralateral
lung. Lung complications such as radiation pneumonitis
are likely to be higher with multi-field techniques such as
IMRT or VMAT in comparison to 3DCRT, where op-
posed beams from 0 and 180 degrees are usually used,
thereby optimally sparing the contralateral lung. With re-
gard to dose escalation and lung sparing surgery, protons
might prove superior to IMRT/VMAT. Severe complica-
tions of the lung with grade 4 and 5 pneumonitis after
IMRT have been reported [7,12]. Since then, special atten-
tion to the contralateral lung dose has been given during
the treatment planning process and pneumonitis rates
should be lower today. Intuitively, the use of HCRT should
reduce toxicity and complication probabilities of esopha-
gus, heart, liver and kidney, however no data with regard
to these toxicity endpoints comparing both treatment
techniques are available.
In recent years, the need for extensive surgery has
been questioned, and less radical surgery has been ad-
vocated such as pleurectomy/decortication. In the con-
text of reduced surgery, the anatomical situation
makes it difficult for RT to be applied to the entire
pleural space, however, it can still be considered as a
targeted local postoperative option in case of incom-
plete resection. Future clinical studies are required to
define the role of radiotherapy in combination with
lung sparing surgery.
Conclusions
In summary, the use of HCRT for treatment of patients
with MPM after EPP is likely to improve local control
rates. The local control improvement did not improve
the overall survival due to the high rates of distant re-
lapses in this series. Further improvement of trimodal or
systemic therapy is required to tackle the high risk of
distant recurrences.
Table 3 Locoregional recurrences in patients who underwent 3D-conformal radiotherapy
Localization Age/sex Histology Time to recurrence Dose in recurrence region
(Months) (Gray)
In-field recurrence 61/m Epithelioid 21 50
In-field recurrence 68/m Biphasic 16 36
In-field recurrence 68/m Epithelioid 13 30
In-field recurrence 65/m Biphasic 19 56
In-field recurrence 65/m Biphasic 16 50
In-field recurrence 50/m Epithelioid 29 48
In-field recurrence 55/m Biphasic 8 50
In-field recurrence 66/m Biphasic 20 36, 501
In-field recurrence 68/m Epithelioid 11 32–43, 46–501
In-field recurrence 58/m Epithelioid 9 50
In-field recurrence 58/m Epithelioid 11 50
In-field recurrence 65/m Biphasic 19 30
Marginal miss recurrence 55/m Epithelioid 19 18
Regional recurrence 62/m Epithelioid 13 Not available
Unknown 56/m Epithelioid 13 Not available
1The recurrence occurred in two separate regions.
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